Onxeo S.A. announced the appointment of Dr. Shefali Agarwal as President. Dr. Agarwal succeeds Julien Miara, a Principal at Invus SAS, who was named interim CEO in January 2022. Dr. Agarwal is a physician by training, and, until recently, was the Chief Medical and Development Officer at Epizyme Inc. where she led global clinical development and regulatory strategy.

She will remain an advisor to Epizyme in a consultant role while fulfilling her duties at Onxeo. She is also on the Scientific Advisory Board of Imvax Inc. and is the Founder of Cancer Shakti Foundation.